Tecfidera »

  • Business » Biogen’s Tecfidera Sales Beat
    October 29, 2013, 07:38 GMT

    Shares of Biogen Idec, Inc. (NASDAQ:BIIB) traded to the upside on on Monday morning following promising sales data from the company’s MS drug, Tecfidera. The company reported reported $286 million in third-quarter sales of the high-profile new multiple sclerosis. This data provides fresh evidence that the treatment is off to an impressive launch and exceeding

Iron FX 1.11156/1.11128 2.8
XM Markets 1.09948/1.09928 2
FxPro 1.10184/1.10171 1.3
FXCM 1.13943/1.13912 3.1